The Latin America Lung Cancer Therapeutics Market was worth USD 0.97 billion in 2022 and estimated to be growing at a CAGR of 7.29%, to reach USD 1.37 billion by 2027.
Lung Cancer is an uninhibited expansion of abnormal cells that initiates off in one or both lungs; for the maximum part in the cells that line the air units. The immediate cells don’t form into solid lung tissue but they expand rapidly and form tumors. As cancer becomes bigger and more in number, they decline the lung’s ability to deliver the bloodstream with oxygen.
Air pollution, amplified alcohol consumption, varying lifestyle, smoking, unhealthy food, and no physical activity are the factors indirectly driving the market. Governments in developing economies like the Latin America region are providing awareness among the people about cancer.
The high cost of the treatment and lack of consciousness among the people for initial recognition of cancer are detained for lung cancer therapeutics market
This research report on the Latin America Lung Cancer Therapeutics Market is segmented and sub-segmented into the following categories:
By Treatment Type:
Regionally, Mexico is dominating the Latin America region's lung cancer therapeutics market and estimated to continue its dominance over the forecast period, while Argentina is expected to witness high growth in the coming years.
Prominent companies leading in the Latin American Lung Cancer Therapeutics Market profiled in this report are Boehringer Ingelheim GmbH, Hoffman-La Roche, Pfizer Inc., GlaxoSmithKline, Eli Lilly and Company, Agennix AG, AstraZeneca plc, and Sanofi-Aventis.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]